Locals over the age of 40 with dementia are being being invited to participate in a major clinical trial investigating the effectiveness of a Chinese herbal extract known as Sailuotong in treating the condition.
Sailuotong, or ‘SLT’, was found to have significant positive results in a recent Chinese study, with participants reporting improved memory, language and executive function after 26 weeks of treatment.
The results are highly significant as current available treatment options for vascular dementia are very limited. If the present Australian clinical trial is successful, SLT could become an effective frontline treatment for thousands of people across the world with vascular dementia.
Eligible patients across the Northern Rivers are now being enlisted for the new hospital and clinic sites in Lismore.
Southern Cross University is coordinating the Lismore trial which will be conducted at the University and St Vincent’s Hospital.
‘This is a great project that’s tackling one of the most significant problems in modern healthcare using herbal medicines that has been standardised and quality assured to pharmaceutical specifications,’ said Professor Stephen Myers, Principal Investigator based at Southern Cross University’s NatMed-Research Unit.
‘Southern Cross University is very excited to be participating.’
There are currently over 400,000 Australians living with dementia and vascular dementia is the second most common type of dementia after Alzheimer’s disease.
Without a medical breakthrough, the number of Australians living with dementia is expected to double over the next two decades.